ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)
Public ClinicalTrials.gov record NCT00229684. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-week, Randomised, Parallel-Group, Multi-Centre, Open-Label Study of the Renal Effects of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a prospective 24-week, randomized, parallel-group, multi-center, active-controlled (pioglitazone 45 mg) open-label study designed to assess the effects of tesaglitazar 2 mg per day on components of renal excretion of creatinine in type 2 diabetics. The study comprises a 2-week enrollment period, followed by a 24-week double blind treatment period and an 8-week follow-up period
Study identification
- NCT ID
- NCT00229684
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 45 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2004 (Type not available)
- Primary completion
- Jun 2006 (Actual)
- Completion
- Jun 2006 (Actual)
- Last update posted
- Aug 30, 2011
2004 – 2006
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Pasadena | California | — | — |
| Research Site | Washington D.C. | District of Columbia | — | — |
| Research Site | Gainesville | Florida | — | — |
| Research Site | Miami | Florida | — | — |
| Research Site | Orlando | Florida | — | — |
| Research Site | Augusta | Georgia | — | — |
| Research Site | Columbus | Georgia | — | — |
| Research Site | New Orleans | Louisiana | — | — |
| Research Site | Reno | Nevada | — | — |
| Research Site | Flushing | New York | — | — |
| Research Site | Durham | North Carolina | — | — |
| Research Site | Cleveland | Ohio | — | — |
| Research Site | Columbus | Ohio | — | — |
| Research Site | Tulsa | Oklahoma | — | — |
| Research Site | Cheswick | Pennsylvania | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Nashville | Tennessee | — | — |
| Research Site | Midland | Texas | — | — |
| Research Site | San Antonio | Texas | — | — |
| Research Site | Gig Harbor | Washington | — | — |
| Research Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00229684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2011 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00229684 live on ClinicalTrials.gov.